Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Clinical trial NCT03286530 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03286530
Sponsor: Massachusetts General Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Acute Myeloid Leukemia in Remission Allogeneic Stem Cell Transplantation

Start date: 2017-11-03
Primary completion: 2026-12-01
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.